Acquisition of the novel ABL kinase domain mutation T315L in a relapsed Philadelphia-positive acute lymphoblastic leukemia patient

Leukemia Research

Volumn 36, Issue 1, 2012, Pages

  How, Gee Fung ^a   Müller, Martin C ^b   Lim, Lay Cheng ^a  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; BCR ABL PROTEIN; DASATINIB; IMATINIB; PREDNISOLONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; BLAST CELL; BLOOD CELL COUNT; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CASE REPORT; CYTOGENETICS; DRUG MEGADOSE; DRUG PULSE THERAPY; GENE MUTATION; HUMAN; KARYOTYPE 46,XY; LETTER; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MALE; MOLECULAR CLONING; MULTIPLE CYCLE TREATMENT; NUCLEIC ACID BASE SUBSTITUTION; NUCLEOTIDE SEQUENCE; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; THROMBOCYTE COUNT;

AMINO ACID SUBSTITUTION; BASE SEQUENCE; CATALYTIC DOMAIN; FUSION PROTEINS, BCR-ABL; HUMANS; KARYOTYPE; LEUCINE; MALE; MIDDLE AGED; MUTATION, MISSENSE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECURRENCE; THREONINE;

EID: 83555165928     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.08.011     Document Type: Letter

References (8)

1. Thomas D.A., Faderi S., Cortes J., et al. Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia with hyper-CVAD and imatinib mesylate. Blood 2004, 103(12):4396-4407.
2. Towatari M., Yanada M., Usui N., et al. Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic. Blood 2004, 104(12):3507-3535.
3. Pfeifer H., Wassmann B., Pavlova A., et al. Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de nova Philadelphia-positive acute lymphoblastic leukemia (Ph-positive ALL). Blood 2007, 110(2):727-734.
4. Hofmann W-K., Jones L.C., Lemp N.A., et al. Ph-positive acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. Blood 2002, 99(5):1860-1862.
5. Branford S., Rudzki Z., Walsh S., et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 2002, 99(9):3472-3475.
6. Jones D., Thomas D., Yin G.C., et al. Kinase domain point mutations in Philadelphia. Chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors. Cancer 2008, 113(5):985-994.
7. Branford S., Melo J.V., Hughes T.P. Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?. Blood 2009, 114(27):5426-5435.
8. Soverini S., Colarossi S., Gnani A., et al. Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain. Haematologica 2007, 92(3):401-404.